Falling CSF Synuclein a Harbinger of Parkinson’s Disease?
The last decade has seen study after study confirm that falling amyloid-β (Aβ) in the cerebrospinal fluid (CSF) is an indicator of incipient AD...
ALL NEWS
466 RESULTS
Sort By:
- Most Recent
- Most Commented
News Brief: Muscle-Monitoring Method Earns $1 Million ALS Prize
A painless test of muscle conductivity promises to make clinical trials for amyotrophic lateral sclerosis (ALS) smaller, cheaper, and faster...
In the Blood: What Can Plasma Aβ Tell Us About Alzheimer’s?
For anyone in an AD study who is nervous about a spinal tap, the idea of measuring dementia risk with a simple blood test would be a dream come true...
New Strategy Nets Biomarkers for AD, and More
A new strategy for detecting serum antibodies could have important ramifications for Alzheimer’s disease diagnostics...
Research Brief: How Normal Is Normal? ADNI Data Begs The Question
Researchers report stark differences among cognitively normal people enrolled in the Alzheimer’s Disease Neuroimaging Initiative...
DC: Biomarkers, Parkinson’s—CAMD Needs All Hands on Deck
Speakers focused on the Coalition Against Major Diseases’ goal of garnering approval for biomarkers in AD drug development...
San Diego: Pre-AD Brain Changes May Allow Early Diagnosis
In an ideal future, physicians would diagnose people with incipient Alzheimer’s disease long before memory problems appear...
London: What, No Argument? Speakers Agree on Trials for Familial AD
Part 2 of Alzforum’s coverage continues with what scientists from inside and outside DIAN said about the prospect of such pre-symptomatic trials...
ApoE2 Carriers Have Less Brain Atrophy, AD Pathology in Spinal Fluid
The few people who have an ApoE2 allele enjoy reduced risk of late-onset Alzheimer’s disease...
Indianapolis: Neuroimaging Opens Window to Disease, Better Diagnosis
Frontotemporal dementias pose a challenge for diagnosis because numerous overlapping clinical syndromes are associated with the disease...
An Oligomer Test for PD—Could One for AD Be Close Behind?
Small, soluble oligomers of amyloid-β (Aβ) are now widely believed to be the most toxic form of the peptide...
PPMI: Brain Imaging To Reveal Preclinical Parkinson’s Signature?
PPMI was launched in July with hopes of identifying a biomarker, or set of markers, that tracks the natural course of Parkinson disease...
PPMI: Parkinson's Field’s Answer to ADNI
One of the great challenges with developing treatments for neurodegenerative disorders stems from the capricious nature of disease progression...
Common Ground: Is Aβ the Foundation for Multiple Dementias?
The majority of patients with Parkinson disease eventually develop dementia, but what pathology underlies this decline?...
Triple Confirmation: AD Footprint in CSF of Cognitively Normal People
In clinical research, a first-time finding may rouse intrigue, but it’s generally independent confirmations of the data that give them potential to leave an indelible mark...